IP Library › Granted Patent US 12,465,646
Granted Patent B2
US 12,465,646 · App. 17/311,062 · Granted Nov 11, 2025

Linkers

Inventors: Richard Raz (London, GB); Matthew Wood (Oxford, GB); Caroline Godfrey (Wolvercote, GB); Graham McClorey (Oxford, GB); Subhashis Banerjee (Kolkata, IN); Michael Gait (Cambridge, GB); Miguel Varela (Oxford, GB); Ashling Holland (Oxford, GB)
Assignees: Oxford University Innovation Limited; United Kingdom Research and Innovation
A61K47/542A61K47/64A61K47/645
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,465,646
App. No.
17/311,062
Granted
Nov 11, 2025
Kind
B2
Abstract

The present invention relates to linkers for connecting a carrier molecule to a therapeutic molecule to form a conjugate, in particular linkers formed of amino acids such as glutamic acid, succinic acid, and gamma-aminobutyric acid. The present invention further relates to a conjugate comprising a linker of the invention, and the use of the conjugate in the treatment of various diseases.

Claims (32)

1 . A conjugate or a pharmaceutically acceptable salt or solvate thereof of the structure

wherein the carrier is a peptide consisting of the sequence RBRRBRFQILYBRBR (SEQ ID NO: 70), wherein the peptide is N-acetylated, and

wherein the therapeutic molecule is an antisense oligonucleotide consisting of the sequence 5′-CAGCAGCAGCAGCAGCAGCAG-3′ (SEQ ID NO: 81), wherein the antisense oligonucleotide is a PMO.

2 . A conjugate or a pharmaceutically acceptable salt thereof, of the structure:

wherein the carrier is a peptide consisting of the sequence RBRRBRFQILYBRBR (SEQ ID NO: 70), wherein the peptide is N-acetylated, and

wherein the therapeutic molecule is an antisense oligonucleotide consisting of the sequence 5′-CAGCAGCAGCAGCAGCAGCAG-3′ (SEQ ID NO: 81), wherein the antisense oligonucleotide is a PMO.

3 . A conjugate of the structure:

wherein the carrier is a peptide consisting of the sequence RBRRBRFQILYBRBR (SEQ ID NO: 70), wherein the peptide is N-acetylated, and

wherein the therapeutic molecule is an antisense oligonucleotide consisting of the sequence 5′-CAGCAGCAGCAGCAGCAGCAG-3′ (SEQ ID NO: 81), wherein the antisense oligonucleotide is a PMO.

4 . A pharmaceutically acceptable salt of a conjugate of the structure:

wherein the carrier is a peptide consisting of the sequence RBRRBRFQILYBRBR (SEQ ID NO: 70), wherein the peptide is N-acetylated, and

wherein the therapeutic molecule is an antisense oligonucleotide consisting of the sequence 5′-CAGCAGCAGCAGCAGCAGCAG-3′ (SEQ ID NO: 81), wherein the antisense oligonucleotide is a PMO.

5 . A pharmaceutical composition comprising:

a conjugate or a pharmaceutically acceptable salt or solvate thereof, of the structure:

wherein the carrier is a peptide consisting of the sequence RBRRBRFQILYBRBR (SEQ ID NO: 70), wherein the peptide is N-acetylated, and

wherein the therapeutic molecule is an antisense oligonucleotide consisting of the sequence 5′-CAGCAGCAGCAGCAGCAGCAG-3′ (SEQ ID NO: 81), wherein the antisense oligonucleotide is a PMO; and

a pharmaceutically acceptable carrier.

6 . A pharmaceutical composition comprising:

a conjugate or a pharmaceutically acceptable salt thereof, of the structure:

wherein the carrier is a peptide consisting of the sequence RBRRBRFQILYBRBR (SEQ ID NO: 70), wherein the peptide is N-acetylated, and

wherein the therapeutic molecule is an antisense oligonucleotide consisting of the sequence 5′-CAGCAGCAGCAGCAGCAGCAG-3′ (SEQ ID NO: 81), wherein the antisense oligonucleotide is a PMO; and

a pharmaceutically acceptable carrier.

7 . A pharmaceutical composition comprising:

a conjugate of the structure:

wherein the carrier is a peptide consisting of the sequence RBRRBRFQILYBRBR (SEQ ID NO: 70), wherein the peptide is N-acetylated, and

wherein the therapeutic molecule is an antisense oligonucleotide consisting of the sequence 5′-CAGCAGCAGCAGCAGCAGCAG-3′ (SEQ ID NO: 81), wherein the antisense oligonucleotide is a PMO; and

a pharmaceutically acceptable carrier.

8 . A pharmaceutical composition comprising:

a pharmaceutically acceptable salt of a conjugate of the structure:

wherein the carrier is a peptide consisting of the sequence RBRRBRFQILYBRBR (SEQ ID NO: 70), wherein the peptide is N-acetylated, and

wherein the therapeutic molecule is an antisense oligonucleotide consisting of the sequence 5′-CAGCAGCAGCAGCAGCAGCAG-3′ (SEQ ID NO: 81), wherein the antisense oligonucleotide is a PMO; and

a pharmaceutically acceptable carrier.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 1, 2024
From: RAZ, RICHARD; WOOD, MATTHEW; GODFREY, CAROLINE; MCCLOREY, GRAHAM; BANERJEE, SUBHASHIS; VARELA, MIGUEL; HOLLAND, ASHLING
To: OXFORD UNIVERSITY INNOVATION LIMITED
Reel/Frame 066965/0902 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 1, 2024
From: GAIT, MICHAEL
To: UNITED KINGDOM RESEARCH AND INNOVATION
Reel/Frame 066965/0910 →
Priority Claims (2)
GB 1820020 · Dec 7, 2018 · national
GB 1911405 · Aug 9, 2019 · national
Continuity (1)
Related Publication 20220125934A1 · Apr 28, 2022
References Cited (168)
US 7807816B2 · Wilton et al. · 2010 [cited by applicant]
US 7838657B2 · Singh et al. · 2010 [cited by applicant]
US 8324371B2 · Popplewell et al. · 2012 [cited by applicant]
US 8361979B2 · Aartsma-Rus et al. · 2013 [cited by applicant]
US 8575305B2 · Gait et al. · 2013 [cited by applicant]
US 8637483B2 · Wilton et al. · 2014 [cited by applicant]
US 8741863B2 · Moulton et al. · 2014 [cited by applicant]
US 8835402B2 · Kole et al. · 2014 [cited by applicant]
US 9018368B2 · Wilton et al. · 2015 [cited by applicant]
US 9079934B2 · Watanabe et al. · 2015 [cited by applicant]
US 9161948B2 · Hanson · 2015 [cited by applicant]
US 9238052B2 · Kameyama et al. · 2016 [cited by applicant]
US 9302014B2 · Gait et al. · 2016 [cited by applicant]
US 9447417B2 · Sazani et al. · 2016 [cited by applicant]
US 9528109B2 · De Kimpe et al. · 2016 [cited by applicant]
US 9582637B1 · Fernandez et al. · 2017 [cited by applicant]
US 9926557B2 · De Kimpe et al. · 2018 [cited by applicant]
US 10160969B2 · Meena et al. · 2018 [cited by applicant]
US 10385092B2 · Watanabe et al. · 2019 [cited by applicant]
US 10781450B2 · Wilton et al. · 2020 [cited by applicant]
US 10876114B2 · Van Deutekom · 2020 [cited by applicant]
US 12268749B2 · Wood et al. · 2025 [cited by applicant]
US 20080306001A1 · Liik et al. · 2008 [cited by applicant]
US 20100016215A1 · Moulton et al. · 2010 [cited by applicant]
US 20110105403A1 · Gait et al. · 2011 [cited by applicant]
US 20110269665A1 · Kole · 2011 [cited by applicant]
US 20120289457A1 · Hanson · 2012 [cited by applicant]
US 20140051646A1 · Gait et al. · 2014 [cited by applicant]
US 20140315977A1 · Bestwick et al. · 2014 [cited by applicant]
US 20140342992A1 · Gait · 2014 [cited by examiner]
US 20150183827A1 · Milletti · 2015 [cited by applicant]
US 20150238627A1 · Leger et al. · 2015 [cited by applicant]
US 20150246958A1 · Han · 2015 [cited by examiner]
US 20160237426A1 · Hanson · 2016 [cited by applicant]
US 20190177723A1 · Dickson · 2019 [cited by applicant]
US 20190241892A1 · Van Deutekom · 2019 [cited by applicant]
US 20200131231A1 · Wood et al. · 2020 [cited by applicant]
US 20210024922A1 · Zain-Luqman · 2021 [cited by examiner]
US 20210299263A1 · Wood et al. · 2021 [cited by applicant]
US 20210299264A1 · Wood et al. · 2021 [cited by applicant]
US 20210388353A1 · Popplewell et al. · 2021 [cited by applicant]
US 20220041662A1 · Wood et al. · 2022 [cited by applicant]
US 20220090066A1 · Wood et al. · 2022 [cited by applicant]
US 20220275372A1 · Wood · 2022 [cited by examiner]
US 20220288218A1 · Yokota et al. · 2022 [cited by applicant]
US 20240189434A1 · Godfrey et al. · 2024 [cited by applicant]
US 20240200062A1 · Godfrey et al. · 2024 [cited by applicant]
US 20240299563A1 · Wood et al. · 2024 [cited by applicant]
US 20250177543A1 · Wood et al. · 2025 [cited by applicant]
CN 103619356A · 2014 [cited by applicant]
CN 103998458A · 2014 [cited by applicant]
CN 104837997A · 2015 [cited by applicant]
EP 2394665A1 · 2011 [cited by applicant]
EP 3034074A1 · 2016 [cited by applicant]
EP 2344637B2 · 2018 [cited by applicant]
EP 3443976A1 · 2019 [cited by applicant]
EP 3031920B1 · 2019 [cited by applicant]
GB 2563964A · 2019 [cited by applicant]
JP 2006514602A · 2006 [cited by applicant]
JP 2007509978A · 2007 [cited by applicant]
JP 2009544749A · 2009 [cited by applicant]
JP 2011523557A · 2011 [cited by applicant]
JP 2013531988A · 2013 [cited by applicant]
JP 2014515762A · 2014 [cited by applicant]
JP 2014526238A · 2014 [cited by applicant]
JP 2015522264A · 2015 [cited by applicant]
JP 2018532695A · 2018 [cited by applicant]
RU 2556800C2 · 2015 [cited by applicant]
WO WO199967284A2 · 1999 [cited by applicant]
WO WO200039139A1 · 2000 [cited by applicant]
WO WO2003106491A2 · 2003 [cited by applicant]
WO WO2004097017A2 · 2004 [cited by applicant]
WO WO2005042539A1 · 2005 [cited by applicant]
WO WO2006000057A1 · 2006 [cited by applicant]
WO WO2008012365A2 · 2008 [cited by applicant]
WO WO2008109105A2 · 2008 [cited by applicant]
WO WO2009005793A2 · 2009 [cited by applicant]
WO WO2009144481A2 · 2009 [cited by applicant]
WO WO2009147368A1 · 2009 [cited by applicant]
WO WO2011157713A2 · 2011 [cited by applicant]
WO WO2012012443A2 · 2012 [cited by applicant]
WO WO2012072088A1 · 2012 [cited by applicant]
WO WO2012090150A2 · 2012 [cited by applicant]
WO WO2012150960A1 · 2012 [cited by applicant]
WO WO2013030569A2 · 2013 [cited by applicant]
WO WO2013040429A1 · 2013 [cited by applicant]
WO WO2014001229A2 · 2014 [cited by applicant]
WO WO2014041505A1 · 2014 [cited by applicant]
WO WO2014043544A1 · 2014 [cited by applicant]
WO WO2014052276A1 · 2014 [cited by applicant]
WO WO2015022504A2 · 2015 [cited by applicant]
WO WO2015113922A1 · 2015 [cited by applicant]
WO WO2015155753A2 · 2015 [cited by applicant]
WO WO2015161255A1 · 2015 [cited by applicant]
WO WO2016028187A1 · 2016 [cited by applicant]
WO WO2016154328A2 · 2016 [cited by applicant]
WO WO2017027848A1 · 2017 [cited by applicant]
WO WO2018017190A2 · 2018 [cited by applicant]
WO WO2018053316A1 · 2018 [cited by applicant]
WO WO2019067975A1 · 2019 [cited by applicant]
WO WO2019067979A1 · 2019 [cited by applicant]
WO WO2019067981A1 · 2019 [cited by applicant]
WO WO2020030927A1 · 2020 [cited by applicant]
WO WO2020030928A1 · 2020 [cited by applicant]
WO WO2020115494A1 · 2020 [cited by applicant]
WO WO2020214763A1 · 2020 [cited by applicant]
WO WO2020257489A1 · 2020 [cited by applicant]
WO WO2021003573A1 · 2021 [cited by applicant]
WO WO2021028666A1 · 2021 [cited by applicant]
WO WO2022172019A1 · 2022 [cited by applicant]
WO WO2022192749A2 · 2022 [cited by applicant]
WO WO2022192754A2 · 2022 [cited by applicant]
Cell-Penetrating Peptides: Design, Synthesis, and Applications Dana Maria Copolovici, Kent Langel, Elo Eriste, and Ülo Langel ACS Nano 2014 8 (3), 1972-1994 DOI: 10.1021/nn4057269 (Year: 2014). [cited by examiner]
“Peptide Design,” ThermoFisher Scientific, <https://www.thermofisher.com/us/en/home/life-science/protein-biology/protein-biology-learning-center/protein-biology-resource-library/pierce-protein-methods/peptide-design.htm… [cited by applicant]
Ablan et al., “Charge Distribution Fine-Tunes the Translocation of [alpha]-Helical Amphipathic Peptides across Membranes,” Biophys J. 111(8):1738-49 (2016). [cited by applicant]
Amantana et al., “Pharmacokinetics, biodistribution, stability and toxicity of a cell-penetrating peptide-morpholino oligomer conjugate,” Bioconjug Chem. 18(4): 1325-31 (Jun. 2007). [cited by applicant]
Bahal et al., “In vivo correction of anaemia in beta-thalassemic mice by gammaPNA-mediated gene editing with nanoparticle delivery,” Nature Communications, 7:13304 (2016) (14 pages). [cited by applicant]
Chan et al., “The complexity of antisense transcription revealed by the study of developing male germ cells,” Genomics. 87(6):681-92 (2006). [cited by applicant]
Dutot et al., “Glycosylated cell penetrating peptides and their conjugates to a proapoptotic peptide: Preparation by click chemistry and cell viability studies,” Journal of Chemical Biology, 3(2):51-65 (2010). [cited by applicant]
Dyson et al. “Himiâ sinteticeskih lekarstvennyh vesestv,” Chemistry of Synthetic Drugs. (1964) (9 pages). [cited by applicant]
Egleton et al., “Improved bioavailability to the brain of glycosylated Met-enkephalin analogs,” Brain Research, 881 (1 ):37-46 (2000). [cited by applicant]
Futaki et al., “Translocation of branched chain arginine peptides through cell membranes: Flexibility in the spatial disposition of positive charges in membrane-permeable peptides,” Biochemistry, 41(25):7926-7930 (2002). [cited by applicant]
González-Barriga et al., “Design and analysis of effects of triplet repeat oligonucleotides in cell models for myotonic dystrophy,” Mol Ther Nucleic Acids. 2(3): 1-12 (Mar. 2013). [cited by applicant]
Hammond et al., “Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy,” PNAS, 113(39):10962-10967 (2016). [cited by applicant]
Ibraheem et al., “Gene therapy and DNA delivery systems,” Int J Pharm. 459(1-2): 70-83 (Jan. 2014). [cited by applicant]
Jahn et al., “How to systematically evaluate immunogenicity of therapeutic proteins—regulatory considerations,” N Biotechnol. 25(5):280-6 (2009). [cited by applicant]
Kalafatovic et al., “Cell-Penetrating Peptides: Design Strategies beyond Primary Structure and Amphipathicity,” Molecules. 22(11):1929 (2017) (38 pages). [cited by applicant]
Kontermann et al., “Bispecific antibodies,” Drug Discov Today. 20(7):838-47 (Jul. 2015) (12 pages). [cited by applicant]
Kuznetsova, “Brackets in text of a legal document as a linguistic and cognitive phenomenon,” Vestnik MGOU. N3:37-43 (2015). [cited by applicant]
Lapidot et al., “Genome-wide natural antisense transcription: coupling its regulation to its different regulatory mechanisms,” EMBO Rep. 7(12):1216-22 (2006). [cited by applicant]
Lécorché et al., “Cellular uptake and biophysical properties of galactose and/or tryptophan containing cell-penetrating peptides,” Biochimica et Biophysica Acta, 1818(3):448-457 (2012). [cited by applicant]
Milletti, “Cell-penetrating peptides: classes, origin, and current landscape,” Drug Discov Today. 17(15-16):850-860 (2012). [cited by applicant]
Nan et al., “Antisense Phosphorodiamidate Morpholino Oligomers as Novel Antiviral Compounds,” Front Microbiol. 9: 1-15 (Apr. 2018). [cited by applicant]
Osman et al., “Morpholino antisense oligonucleotides targeting intronic repressor Element1 improve phenotype in SMA mouse models,” Human Molecular Genetics, 23(18):4832-4845 (2014). [cited by applicant]
Pinto et al., “Impeding Transcription of Expanded Microsatellite Repeats by Deactivated Cas9,” Mol Cell. 68(3): 479-490 (Nov. 2017). [cited by applicant]
Pokrovskij V. I. “Populârnaâ medicinskaâ enciklopediâ [Popular Medical Encyclopedia],” Ul'ânovsk “Knigocej”, 4th ed., 1997, p. 317 (drugs) (2 pages). [cited by applicant]
Rothbard et al., “Arginine-rich molecular transporters for drug delivery: Role of backbone spacina in cellular uptake,” Journal of Medicinal Chemistry, 45(17):3612-8 (2002). [cited by applicant]
Rydberg et al. “Effects of Tryptophan Content and Backbone Spacing on the Uptake Efficiency of Cell-Penetrating Peptides,” Biochemistry. 51(27):5531-5539 (Jun. 28, 2021) (9 pages). [cited by applicant]
Rydberg et al., “Effects of tryptophan content and backbone spacing on the uptake efficiency of cell-penetrating peptides,” Biophysical Journal, Board B253. 102(3):487a (2012). [cited by applicant]
Shabanpoor et al., “Bi-specific splice-switching PMO oligonucleotides conjugated via a single peptide active in a mouse model of Duchenne muscular dystrophy,” Nucleic Acids Res. 43(1):29-39 (2015). [cited by applicant]
Shabanpoor et al., “Development of a general methodology for labelling peptide-morpholino oligonucleotide conjugates using alkyne-azide click chemistry,” Chem Commun (Camb). 49(87):10260-2 (2013) (9 pages). [cited by applicant]
Shabanpoor et al., “Identification of a peptide for systemic brain delivery of a morpholino oligonucleotide in mouse models of spinal muscular atrophy,” Nucleic Acid Therapeutics. 27(3):130-143 (2017) (15 pages). [cited by applicant]
Shen et al., “Single variable domain-IgG fusion. A novel recombinant approach to Fc domain-containing bispecific antibodies,” J Biol Chem. 281(16):10706-14 (2006). [cited by applicant]
Swenson et al., “Chemical modifications of antisense morpholino oligomers enhance their efficacy against Ebola virus infection,” Antimicrob Agents Chemother. 53(5): 2089-99 (May 2015). [cited by applicant]
Torres et al., “The immunoglobulin constant region contributes to affinity and specificity,” Trends Immunol. 29(2):91-7 (2008). [cited by applicant]
Wermuth et al., “Glossary of terms used in medicinal chemistry,” Pure & Appl. Chem. 70(5):1129-43 (1998). [cited by applicant]
Witt et al., “Peptide drug modifications to enhance bioavailability and blood-brain barrier permeability,” Peptides. 22(12):2329-2343 (2001). [cited by applicant]
Wu et al., “Long-term rescue of dystrophin expression and improvement in muscle pathology and function in dystrophic mdx mice by peptide-conjugated morpholino,” Am J Pathol. 181(2): 392-400. (Aug. 2012). [cited by applicant]
Yin et al., “Pip5 Transduction Peptides Direct High Efficiency Oligonucleotide-mediated Dystrophin Exon Skipping in Heart and Phenotypic Correction in mdx Mice,” Molecular Therapy, 19(7):1295-1303 (2011). [cited by applicant]
Zhou et al., “A Novel Morpholino Oligomer Targeting ISS-N1 Improves Rescue of Severe Spinal Muscular Atrophy Transgenic Mice,” Human Gene Therapy. 24(3):331-342 (2013). [cited by applicant]
Zorko et al., “Cell-penetrating peptides: mechanism and kinetics of cargo delivery,” Adv Drug Deliv Rev. 57(4):529-45 (2005). [cited by applicant]
{circumflex over (R)}ihá{umlaut over (c)}ek et al. [New Indings in Methotrexate Pharmacology—Diagnostic Possibilities and Impact on Clinical Care] Klin Onkol. 2015;28(3):163-70. doi: 10.14735/amko2015163. (abstract only… [cited by applicant]
Betts et al., “Pip6-PMO, A New Generation of Peptide-oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity for DMD Treatment,” Molecular Therapy-Nucleic Acids, 1(8): e38 (2012). [cited by applicant]
Borrelli et al., “Cell Penetrating Peptides as Molecular Carriers for Anti-Cancer Agents,” Molecules, 23(2): pp. 1-28 (2018). [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/GB2019/053445 dated Feb. 28, 2020. [cited by applicant]
Lehto et al., “Peptides for nucleic acid delivery,” Advanced Drug Delivery Reviews, 106: 172-182 (2016). [cited by applicant]
McClorey et al., “Cell-Penetrating Peptides to Enhance Delivery of Oligonucleotide-Base Therapeutics,” Biomedicines, 6(2): 51 (15 pages)(2018). [cited by applicant]
Wu et al., “Cell-penetrating peptides as transporters for morpholino oligomers: effects of amino acid composition on intracellular delivery and cytotoxicity,” Nucleic Acids Research, 35(15): 5182-5191 (2007). [cited by applicant]
Alaybeyoglu et al., “Insights into membrane translocation of the cell-penetrating peptide pVEC from molecular dynamics calculations.” Journal of Biomolecular Structure and Dynamics. 34(11): 2387-2398 (2016) (14 pages). [cited by applicant]
Deuss et al., “Parallel synthesis and splicing redirection activity of cell-penetrating peptide conjugate libraries of a PNA cargo.” Organic & Biomolecular Chemistry. 11:7621-7630 (2013) (10 pages). [cited by applicant]
Dimachkie et al., “Distal myopathies,” available in PMC Aug. 1, 2015, published in final edited form as: Neurol Clin. 32(3):817-42 (Aug. 2014) (Epub May 2014) (32 pages). [cited by applicant]
Godfrey et al., “How much dystrophin is enough: the physiological consequences of different levels of dystrophin in the mdx mouse.” Human Molecular Genetics. 24(15):4225-4237 (May 1, 2015) (13 pages). [cited by applicant]
Haurum et al., “Presentation of Cytosolic Glycosylated Peptides by Human Class I Major Histocompatibility Complex Molecules In Vivo”. Journal of Experimental Medicine. 190(1): 145-150 (Jul. 5, 1999) (6 pages). [cited by applicant]
Lehto et al., “Cellular trafficking determines the exon skipping activity of Pip6a-PMO in mdx skeletal and cardiac muscle cells.” Nucleic Acids Res. 42(5):3207-3217 (Dec. 23, 2013) (11 pages). [cited by applicant]
Marks et al., “Spontaneous Membrane-Translocating Peptides by Orthogonal High-Throughput Screening.” Journal of the American Chemical Society. 133: 8995-9004 (May 5, 2011) (10 pages). [cited by applicant]
Nikolenko et al., “Rehabilitation of children with progressive muscular dystrophy Duchenne,” Russian Bulletin of Perinatology and Pediatrics. 4:28-31 (2014). [cited by applicant]
Berezov T. T. et al., Biologičeskaâ himiâ [Biological Chemistry], Moscow, “Medicine”, 1998, p. 34 third para., p. 59 last para (3 pages). [cited by applicant]
LifeTein (<https://www.lifetein.com/Peptide_Modifications_Pegylation_Linker. html?srsltid=AfmBOooYB4PzPAyhHF6IPK1QKG6LeqO0dw4Q_DMII6Nza-fRFSJnlx8G>Oct. 21, 2014). Retrieved on Apr. 5, 2025 (8 pages). [cited by applicant]
Cited By (1)
US 12,673,108